Cambodia

Keywords: Tuberculosis, Malaria

2015 Activities  2015 International Activity Report

In 2015, a project providing prevention, screening with advanced diagnostics and treatment for artemisinin-resistant strains of malaria was launched in Preah Vihear province.

Resistance to artemisinin, currently the most effective antimalarial drug, has been identified in certain parts of Cambodia, and this means that the disease is becoming more difficult to treat and eliminate in these areas. If the resistant parasites spread beyond the Mekong region and reach other parts of Asia or Africa, they would pose a huge public health threat, as was the case when parasites became resistant to earlier antimalarial drugs. MSF has opened a project in Preah Vihear province, where there is proven resistance to artemisinin. This is an underdeveloped and remote border region, where population movement and a lack of healthcare make malaria hard to control. The new project targets the most at-risk people, and focuses on researching how resistant malaria is transmitted and evaluating which strategies could contribute to the elimination of the disease locally. Throughout the year, MSF worked with the Ministry of Health and the communities to increase awareness and case detection.

Treating tuberculosis (TB) in Kampong Cham

MSF started to hand over the last of its comprehensive TB care programmes in Kampong Cham province this year, including activities in Cheung Prey, to the Cambodian health authorities and other organisations. The team transferred the resources required for the screening, detection, treatment and follow-up of TB patients. The project closed at the end of 2015, with final patient follow-up planned for June 2016.

Staff also carried out three rounds of active TB case-finding in 2015, in Tboung Khmum and Krouch Chhmar districts.

While this brings MSF’s response to TB to a close in the country, an agreement has been reached with health authorities to open a hepatitis C programme in 2016.

Year MSF first worked in the country: 1979.

 

2015 Key figures
Patients under treatment for TB 640
No. staff in 2015 109
2015 Expenditure €1.8 million

Figures from 2015 International Activity Report
and 2015 International Financial Report

 

Sort by: